Diagnostics and therapy of Alzheimer's disease

Indian Journal of Experimental Biology

Volumn 45, Issue 4, 2007, Pages 315-325

  Mikiciuk Olasik, Elzbieta ^a   Szymański, Paweł ^a   Zurek, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Alzheimer's disease; Diagnostic; Pet; Spect

Indexed keywords

ALZHEIMER DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34250192903     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lewczuk J, Farmakoterapia oraz alternatywne formy leczenia choroby Alzheimera, Farmacja Polska, 60 (2004) 22.
2. Gauthier S, Advances In the pharmacotherapy of Alzheimer's disease, JMAC, 165 (2002) 616.
3. Sugimoto H, Ogura H & Arai Y, Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor, Jpn J Pharmacol, 89 (2002) 7.
4. Delagarza V W, Pharmacologic Treatment of Alzheimer's Disease: An Update, Am Family Physician 68 (2003) 1366.
5. Wolfe M S, Secretase targets for Alzheimer's disease: Identification and therapeutic potential, J Med Chem, 44 (2001) 2060.
6. Yu G & Nishimura M, Nicastrin modulates presenilinmediated notch/glp-1 signal transduction and β APP processing, Nature, 407 (2000) 48.
7. Camps P & Munoz-Torrero, D, Cholinergic drugs in pharmacotherapy of Alzheimer's disease, Mini Rev Med Chem, 2 (2002) 25.
8. Francis P, Palmer A, Snape M, The cholinergic hypothesis of Alzheimer's disease: a review of progress, J Neurol Neurosurg Psychiatry, 66 (1999) 137.
9. Holden M & Kelly C, Use of cholinesterase inhibitors in dementia, Ad Psych Treat, 8 (2002) 89.
10. Contreras M J Parrot I & Sippl W, Design, synthesis and structure-activity relationship of a series of 3-[2-(1- Benzylpiperidin-4-yl) ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors, J Med Chem, 44 (2001) 2707.
11. Ott B R, Medical treatment of Alzheimer's disease: Past, present and future, Medicine and Health/Rhode Island, 85 (2002) 210.
12. Doucet-Personeni C, Bentlej P & Fletcher R, A structurebased design approach to the development of novel, reversible ache inhibitors, J Med Chem, 44 (2001) 3203.
13. Malawska B, Kierunki poszukiwania nowych lekó w wpł ywaja̧cych na procesy uczenia i zapamiȩtywania, poprawiaja̧cych rozpoznawanie, Wiadomości Chemiczne, 55 (2001) 67.
14. Sugimoto H, Structure-activity relationships of acetylcholinesterase inhibitors: Donepezil hydrochloride for the treatment of Alzheimer's Disease, Pure Appl Chem, 71 (1999) 2031.
15. Yu Q, Holloway H & Flippen-Anderson J, Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action, J Med Chem, 44 (2001) 4062.
16. Bolognesi M L & Andrisano V, Hexahydrochromeno[4, 3- b]pyrrole Derivatives as Acetylcholinesterase Inhibitors, J Med Chem, 44 (2001) 105.
17. Savini L, Campiani G & Geata A, Novel and potent tacrinerelated hetero - and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase, Bioorg Med Chem Lett, 13 (2001) 1779.
18. Bruhlmann C, Ooms F & Carrupt P, Coumarins Derivatives as Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase, .J Med Chem, 44 (2001) 3195.
19. Pauly J R, Nicotinic Cholinergic Receptor Deficits in Alzheimer's Disease: Where's the Smoke?, Alzheimer's Dis Rev, 3 (1998) 28.
20. Religa D & Winblad B, Terapeutic strategies for Alzheimer's disease based on new molecular mechanisms, Acta Neurobiol Exp, 63 (2003) 393.
21. Krzymiński S, Postȩpy Psychiatrii i Neurologii, 4 (1995) 21.
22. Mikiciuk-Olasik, E, Szymański P & Żurek E, Rola radiofarmacji w diagnostyce choroby Alzheimera, Farmacja Polska, 16 (2004) 732.
23. C]flumazenil, Brain, 123 (2000) 2289.
24. Hoepping A, TROTEC-1, a new high-affinity ligand for labeling of the dopamine transporter, J Med Chem, 41 (1998) 4429.
25. Maclean D & Padgett H, Drug and probes: The symbiotic relationship between pharmaceutical discovery and imaging science, Mol Imaging Biol, 5 (2003) 304.
26. Jagust W, Molecular Neuroimaging in Alzheimer's Disease, NeuroRx, 1 (2004) 206.
27. Walecki J & Ziemiański A, Rezonzns Magnetyczny i Tomografia Komputerowa w praktyce klinicznej. Sprinter PWN, Warszawa (1979).
28. Ushijima Y & Okuyama C, Relationship between cognitive function and regional cerebral blood flow in Alzheimer's disease, Nucl Med Comm, 23 (2002) 779.
29. Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping, Eur J Nucl Med, 29 (2002) 615.
30. Tc- ECD SPECT, MRI and neuropsychological testing in senile dementia of the Alzheimer type, Nucl Med Comm, 22 (2001) 713.
31. Phelps M, Positron emission tomography provides molecular imaging of biological processes, PNAS, 29 (2002) 1685.
32. Devous M, Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies, Eur J Nucl Med, 29 (2002) 1685.
33. C]donepezil as tracer for visualization of acetylcholinesterase by PET, Nucl Med Biol, 27 (2000) 745.
34. Akula M & Longford C, Synthesis of 9-amino-7- [18F]fluoro-1, 2, 3, 4-tetrahydroacridine: A potential PET agent to map acetylcholinesterase in Alzheimer patients, Second Annual Research Day University of Tennessee Medical Center in Knoxvill TN, 42 (1998) 539.
35. I]iodotacrine: a potential SPECT agent to map acetylcholinesterase, J Labelled Compd Radiopharm, 42 (1999) 959.
36. C]methyl-tetrahydroaminoacridine (methyl-tacrine) in baboon brain, Eur J Pharm, 236 (1993) 229.
37. Herholz K & Lercher M, PET measurment of cerebral acetylcholine esterase activity without blood sampling, Eur J Nucl Med, 28 (2001) 472.
38. Shinoth H & Aotsuka A, . Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET, Neur, 56 (2001) 408.